3-(3-Bromo-prop-1-ynyl)-benzoic acid methyl ester | 272130-56-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3-Bromo-prop-1-ynyl)-benzoic acid methyl ester
• 英文别名: Methyl 3-(3-bromoprop-1-yn-1-yl)benzoate；methyl 3-(3-bromoprop-1-ynyl)benzoate
• CAS: 272130-56-0
• 化学式: C₁₁H₉BrO₂
• 分子量: 253.095
• InChiKey: RWCZTXJZDVJBIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(3-Bromo-prop-1-ynyl)-benzoic acid methyl ester 在 sodium hydroxide 、 sodium tetrahydroborate 、 sodium hydride 、 sodium iodide 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-[3-(8-hydroxy-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-3-yl)prop-1-ynyl]benzoic acid
  参考文献：
  名称：

  AMP Deaminase Inhibitors. 3. SAR of 3-(Carboxyarylalkyl)coformycin Aglycon Analogues

  摘要：

  N3-Substituted coformycin aglycon analogues with improved AMP deaminase (AMPDA) inhibitory potency are described. Replacement of the 5-carboxypentyl substituent in the lead AMPDA inhibitor 3-(5-carboxypentyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (2) described in the previous article with various carboxyarylalkyl groups resulted in compounds with 10-100-fold improved AMPDA inhibitory potencies. The optimal N3 substituent had m-carboxyphenyl with a two-carbon alkyl tether. For example, 3-[2-(3-carboxy-5-ethylphenyl)-ethyl]-3,6,7,8-tetrahydroimidazo[4,5-d] [1,3]diazepin-8-ol (43g) inhibited human AMPDA with a K-i = 0.06 mu M. The compounds within the series also exhibited >1000-fold specificity for AMPDA relative to adenosine deaminase.

  DOI：

  10.1021/jm990448e
• 作为产物：
  描述：

  3-碘苯甲酸甲酯 在 bis-triphenylphosphine-palladium(II) chloride 、 四溴化碳 、 三乙胺 、 三苯基膦 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 3-(3-Bromo-prop-1-ynyl)-benzoic acid methyl ester
  参考文献：
  名称：

  AMP Deaminase Inhibitors. 3. SAR of 3-(Carboxyarylalkyl)coformycin Aglycon Analogues

  摘要：

  N3-Substituted coformycin aglycon analogues with improved AMP deaminase (AMPDA) inhibitory potency are described. Replacement of the 5-carboxypentyl substituent in the lead AMPDA inhibitor 3-(5-carboxypentyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (2) described in the previous article with various carboxyarylalkyl groups resulted in compounds with 10-100-fold improved AMPDA inhibitory potencies. The optimal N3 substituent had m-carboxyphenyl with a two-carbon alkyl tether. For example, 3-[2-(3-carboxy-5-ethylphenyl)-ethyl]-3,6,7,8-tetrahydroimidazo[4,5-d] [1,3]diazepin-8-ol (43g) inhibited human AMPDA with a K-i = 0.06 mu M. The compounds within the series also exhibited >1000-fold specificity for AMPDA relative to adenosine deaminase.

  DOI：

  10.1021/jm990448e

文献信息

• Palladium-catalysed construction of butafulvenes
  作者：Xin Huang、Bing-Zhi Chen、Pengbin Li、Ding-Wei Ji、Jinxian Liu、Hao Zheng、Sa-Na Yang、Yan-Cheng Hu、Boshun Wan、Xiang-Ping Hu、Chunling Fu、Yankai Huang、Jian Zheng、Qing-An Chen、Shengming Ma

  DOI：10.1038/s41557-022-01017-9

  日期：2022.10

  of the intrinsic high strain energy and anti-aromaticity, the preparation of butafulvene compounds has been a fundamental issue for the development of butafulvene chemistry. Here an efficient palladium-catalysed coupling protocol involving propargylic compounds has been developed, providing a solid and versatile strategy for the rapid assembly of symmetric butafulvene derivatives. Based on mechanistic

  丁富烯是苯的结构异构体，包含带有两个环外共轭亚甲基单元的环丁烯骨架。由于其固有的高应变能和抗芳香性，丁富烯化合物的制备一直是丁富烯化学发展的一个基本问题。在这里，已经开发出一种涉及炔丙基化合物的高效钯催化偶联方案，为对称丁富烯衍生物的快速组装提供了可靠且通用的策略。基于机理研究，已经证实了两种互补的机理，都涉及钯催化。随着机理的揭示，也实现了非对称丁富烯的合成。该策略的优点包括对广泛的炔丙基分子的耐受性，温和的反应条件，简单的催化系统和易于扩展。该产品作为环丁烯衍生物的平台分子的合成潜力也已得到证实。
• AMP Deaminase Inhibitors. 3. SAR of 3-(Carboxyarylalkyl)coformycin Aglycon Analogues
  作者：Srinivas Rao Kasibhatla、Brett C. Bookser、Gary Probst、James R. Appleman、Mark D. Erion

  DOI：10.1021/jm990448e

  日期：2000.4.1

  N3-Substituted coformycin aglycon analogues with improved AMP deaminase (AMPDA) inhibitory potency are described. Replacement of the 5-carboxypentyl substituent in the lead AMPDA inhibitor 3-(5-carboxypentyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (2) described in the previous article with various carboxyarylalkyl groups resulted in compounds with 10-100-fold improved AMPDA inhibitory potencies. The optimal N3 substituent had m-carboxyphenyl with a two-carbon alkyl tether. For example, 3-[2-(3-carboxy-5-ethylphenyl)-ethyl]-3,6,7,8-tetrahydroimidazo[4,5-d] [1,3]diazepin-8-ol (43g) inhibited human AMPDA with a K-i = 0.06 mu M. The compounds within the series also exhibited >1000-fold specificity for AMPDA relative to adenosine deaminase.